Skip to main content

Radiotherapy is one of the main treatments for cancer and is used as an independent treatment or in combination with surgery and/or systemic treatment (i.e. chemotherapy). The goal is to cure cancer, to augment the prognosis, or to palliate symptoms.

Radiation therapy has a biological effect on the DNA and the inflammatory status of the tumor. The side effects are decreased by modern techniques that allow to paint the dose more precisely.

The proposed treatment is discussed with the patient at consultation, usually after multidisciplinary discussion. The radiation oncologist follows the patient throughout the radiotherapy treatment and takes part in the follow-up after therapy, in close collaboration with the other health professionals.

Research projects

Our dedicated research page provides a more comprehensive overview of our research activities. Below we show some examples of current research projects.

Project 1

Swall PEG study: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in oropharyngeal cancer patients treated with definitive chemoradiotherapy.
  • Project leaders : Tatiana Dragan, Dirk Van Gestel
  • Trial sponsor : Institut Jules Bordet
  • Funding : Les Amis de l’Institut Bordet
  • Collaboration : CHU Saint-Pierre, Universitair Ziekenhuis Gent

Project 2

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Project 3

ProCaLung  – The Project on Cancer of the Lung
  • Project leadersFlorian Charlier, Luigi Moretti
  • Trial sponsor: Belgian College of Physicians for Radiotherapy Centers
  • Funding: Belgian College of Physicians for Radiotherapy Centers and “Les Amis de l’Institut Bordet”
  • Collaboration: Other ProCaLung Team members: Xavier Geets (Cliniques Universitaires Saint-Luc), Maarten Lambrecht (UZLeuven), Yolande Lievens (UZGent), Vincent Remouchamps (CHU-UCL Namur - Site Ste Elizabeth)

Project 4

Contribution to the study of stereotaxic radiotherapy and its immunomodulatory effect in the treatment of pancreatic cancers.
  • Project leaders : Bouchart ChristelleLuigi Moretti
  • Trial sponsor : Institut Jules Bordet
  • Funding : « Fonds de la Recherche Scientifique – FNRS », « Les Amis de l’Institut Bordet », « Fondation contre le Cancer ».
  • Collaboration : Hopital Erasme, Molecular Immunology Lab (MIU, Institut J. Bordet ULB), Laboratory of Medical and Molecular Oncology (LMMO, VUB), CHU Saint-Pierre, CHR Namur and all the hospitals of the ULB network.

Project 5

Randomized trial to quantify the efficacy of the Safetac® product Mepitel® Film on the prevention of radiodermatitis in the inguinal fold.
  • Project leader : Van de Ven Gitte
  • Trial sponsor : Institut Jules Bordet
  • Funding : Mölnlycke

Projet 6

Evaluation of a clinical decision support protocol during radiotherapy for H&N cancer patients
  • Projectleaders : Filipa Rodrigues Sousa, Younes Jourani
  • Trial sponsor : Institut Jules Bordet

Our team

Head of Department
- Prof 
Dirk Van Gestel : head and neck tumours, skin tumours, non-malignant tumours, sarcomas, breast tumours.

Medical Physics Department
The radiotherapy physics’ team is part of the central Medical Physics Department of the Institute.
Prof Nick Reynaert, Head of Medical Physics Department:
Mr Younes Jourani, Responsible for physics in radiotherapy:

Head of technologists
Mrs Monica Somoano Tarno

Radiation Oncologists
- Dr Imane Ahrouch: breast and gynaecological tumours, brachytherapy
- Dr 
Sylvie Beauvois : head and neck and skin tumours
- Dr 
Christelle Bouchart : pancreatic and neurological tumours
- Dr 
Antoine Desmet : breast and skin tumours, intraoperative radiotherapy and brachytherapy
- Dr 
Tatiana Dragan : head and neck tumours, sarcomas
- Dr Guillaume Janoray: breast and urological tumours, brachytherapy

- Prof. Philippe Martinive : neurological, digestive and pediatric tumours
- Prof. 
Luigi Moretti : digestive and thoracic tumours
- Dr 
François-Xavier Otte : urological tumours
- Dr 
Catherine Philippson : breast tumours and intraoperative radiotherapy
- Dr 
Martine Roelandts : thoracic tumours and lymphomas
- Dr 
Robbe Van den Begin : oligometastatic, urological and digestive tumours
- Prof. Honorary 
Paul Van Houtte : thoracic and gynecological tumours, non-malignant tumours, brachytherapy

- Dr Alex De Caluwé : Research consultant
- Prof. Philippe Lambin: Research Consultant

Radiation Oncologists in training
- Dr Mathilde Baré
- Dr Sofian Benkhaled
- Dr Florian Charlier
- Dr Thomas Descamps

- Dr Emmanuel Fardeau
- Dr Nicolas Jullian
- Dr Martin Mandelier
- Dr Kaoutar Soussy
- Dr Pauline De Bruyn
- Dr Delavigne Marie-Elise
- Dr Bertrand Donneaux
- Dr Hamza Ghassan

ICSO radiotherapy
The coordinating nurse in radiotherapy supports the patients in organizing their multidisciplinary care, in the first place for the patients referred by other centers.
- Mrs Ysabelle Houtekens

Quality Manager
- Mr John Vercauteren

- Mrs Amaryllis N’Tumba
- Mrs Carine Top
- Mrs Carine Vandevelde


 Scientific publications

EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score.

Authors : Figueiredo M, Bouchart C, Moretti L, Mans L, Engelholm JL, Bali MA, Van Laethem JL, Eisendrath P
Year : 2021
Journal : Endosc Int Open
Volume : 9
Pages : E253-E257

Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma.

Authors : Giraud P, Racadot S, Vernerey D, Goldstein D, Glimelius B, Van Houtte P, Gubanski M, Spry N, Van Laethem JL, Hammel P, Huguet F
Year : 2021
Journal : Int J Radiat Oncol Biol Phys
Volume : 110
Pages : 993-1002

Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma.

Authors : Schernberg A, Vernerey D, Goldstein D, Van Laethem JL, Glimelius B, Van Houtte P, Bonnetain F, Louvet C, Hammel P, Huguet F
Year : 2021
Journal : Int J Radiat Oncol Biol Phys
Volume : 110
Pages : 1022-1031

Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency.

Authors : Kry SF, Lye J, Clark CH, Andratschke N, Dimitriadis A, Followill D, Howell R, Hussein M, Ishikawa M, Kito S, Kron T, Lee J, Michalski J, Filippo Monti A, Reynaert N, Taylor P, Venables K, Xiao Y, Lehmann J
Year : 2021
Journal : Radiother Oncol
Volume : 159
Pages : 106-111

Editorial: Quality Assessment Across Disciplines in Head and Neck Cancer Treatment.

Authors : Vermorken JB, Van Gestel D
Year : 2021
Journal : Front Oncol
Volume : 11
Pages : 636622